Medical Device Global Market Access Podcast Por Pure Global arte de portada

Medical Device Global Market Access

Medical Device Global Market Access

De: Pure Global
Escúchala gratis

Navigate every market. Accelerate every launch. Medical Device Global Market Access by Pure Global is the audio briefing that turns the world’s most confusing regulatory pathways into clear, actionable roadmaps. If you’re a MedTech founder, RA/QA leader, product manager, or investor who needs to get devices cleared anywhere from Austin to Abu Dhabi, this show is your shortcut. Why listen? • Step-by-step playbooks – We decode EU MDR, U.S. 510(k), Brazil’s ANVISA, China’s NMPA, and 25 + other regimes, showing exactly how long each milestone really takes and where companies get stuck. • First-hand war stories – Hear candid interviews with regulatory veterans who have shepherded implants, software, wearables, diagnostics, and AI algorithms to market—and lived to tell the tale. • Real-time intelligence – Every episode covering the week’s new guidances, standards, and enforcement trends so you’re always ahead of the curve. • Actionable templates – From clinical evaluation checklists to technical-file skeletons, we break down the documents you’ll need and the pitfalls reviewers love to flag. • AI-powered insights – Because Pure Global mines millions of public filings, tenders, and recalls, we surface data-backed best practices you won’t hear at conferences—or from competitors. What you’ll hear • Launching SaMD under multiple risk classes in parallel • Surviving an unannounced ISO 13485 audit • Building a “reg-first” QMS that scales • Mastering Latin-American registrations without endless language cycles • Leveraging real-world evidence to shorten clinical timelines • Aligning cybersecurity, privacy, and post-market surveillance rules across regions Whether you’re plotting first entry, managing lifecycle expansions, or rescuing a delayed submission, subscribing could shave months—and millions—off your path to revenue. ⸻ Brought to you by Pure Global – the AI-native consultancy that already guides MedTech innovators through regulatory and market-access hurdles in 30 + countries. Ready for expert help on your next submission? Visit https://pureglobal.com or email info@pureglobal.com to start accelerating today.Copyright 2026 Pure Global
Episodios
  • AI Diagnostic Bias: Navigating FDA and Global Regulations to Avoid Market Withdrawal

    AI Diagnostic Bias: Navigating FDA and Global Regulations to Avoid Market Withdrawal
    Mar 12 2026
    This episode explores the growing regulatory pressure on medical device manufacturers to mitigate algorithmic bias in AI-powered diagnostics. We discuss why "black box" algorithms are facing scrutiny, what bodies like the FDA are now requiring as evidence of equitable performance, and the significant risks of failing to address bias, including market withdrawal. - What is "algorithmic bias" in the context of AI medical devices? - Why are regulators demanding transparency in AI models? - What specific evidence must manufacturers provide to prove their AI performs equitably across diverse populations? - How has FDA guidance on AI bias evolved since 2021? - What are the financial and reputational risks of a biased diagnostic tool? - How can you integrate bias mitigation into your product's entire lifecycle? - What documentation is now essential for your technical file and marketing submission? - Can failure to address AI bias lead to a product recall? Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies navigating complex challenges like AI bias. Our experts develop robust regulatory strategies and use advanced AI tools to efficiently compile technical dossiers that meet the stringent requirements of global authorities like the FDA and EU. We help you demonstrate equitable performance and secure market access for your innovative devices. Ensure your product is ready for global markets by contacting us at info@pureglobal.com or visiting https://pureglobal.com. Explore our free AI-powered regulatory tools and database at https://pureglobal.ai.
    Más Menos
    4 m
  • ASC Sales Strategy: Adapting MedTech for the 2026 Procedure Shift

    ASC Sales Strategy: Adapting MedTech for the 2026 Procedure Shift
    Mar 11 2026
    This episode explores the strategic pivot required for MedTech companies as over 500 surgical procedures shift to Ambulatory Surgery Centers (ASCs) by 2026. We break down why traditional hospital-focused sales models are failing in the high-efficiency ASC environment and outline the new logistics, pricing, and value propositions needed to succeed in this rapidly growing market. - Why is the 2026 procedural shift to ASCs a critical challenge for MedTech sales teams? - How do purchasing decisions in an ASC differ from those in a hospital? - What common mistakes do hospital-focused sales teams make when approaching ASCs? - What are the essential logistics and pricing models required for the ASC environment? - How can you tailor your value proposition to appeal directly to surgeon-owners? - Is your company prepared for the addition of over 500 procedures to the ASC-approved list? - What specific strategies will win in the competitive Ambulatory Surgery Center market? Pure Global offers end-to-end regulatory consulting to help MedTech companies capitalize on market shifts like the move to ASCs. Our experts develop efficient regulatory strategies and conduct market research to identify the best pathways for expansion. By combining local expertise in over 30 markets with advanced AI tools, we streamline the process of getting your product approved and ready for sale. Whether you're a startup or a multinational, we help you navigate complex environments and optimize your product portfolio for new opportunities. Contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and database at https://pureglobal.ai.
    Más Menos
    3 m
  • MedTech's Subscription Shift: Surviving the Death of Hospital Capital Expenditures

    MedTech's Subscription Shift: Surviving the Death of Hospital Capital Expenditures
    Mar 10 2026
    This episode explores the pivotal shift in hospital procurement from traditional capital expenditures (CapEx) to subscription-based Device-as-a-Service (DaaS) models. We analyze why this change is occurring and detail its disruptive impact on medical device manufacturers, covering critical adjustments required in revenue recognition, sales compensation, customer relationships, and even product design to thrive in this new service-oriented landscape. Key Questions - Why are hospitals moving away from large, upfront equipment purchases? - What is included in a "Device-as-a-Service" (DaaS) contract? - How does subscription billing fundamentally change revenue recognition for MedTech companies? - What new sales commission structures are needed for a recurring revenue model? - How does the manufacturer-customer relationship evolve from transactional to a long-term partnership? - What are the implications for product design and durability in a DaaS model? - Can subscription models create a competitive advantage in new international markets? Navigating disruptive commercial models requires a forward-thinking global strategy. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you develop efficient pathways for market access and identify the best countries for expansion. Our unique combination of local expertise and advanced AI tools streamlines the creation of technical dossiers and keeps you ahead of regulatory changes. Let us help you turn market shifts into opportunities. Contact Pure Global at info@pureglobal.com, visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.
    Más Menos
    3 m
Todavía no hay opiniones